CBG for Reducing Tumor Progression
Listen to article
In recent years, the potential therapeutic benefits of cannabinoids have gained significant attention. These compounds, all originating from the hemp plant, have great medical potential and have already helped millions of people with their pain and many other conditions.
While CBD and THC are widely known, another cannabinoid called cannabigerol (CBG) is emerging as a promising compound for reducing tumor progression. CBG offers unique properties that differentiate it from other cannabinoids, making it an exciting area of research in the field of oncology. One of its most notable effects is the role it may serve in reducing tumor progression.
What Is CBG?
Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the cannabis plant. It is often referred to as the “mother cannabinoid” because it serves as a precursor to other cannabinoids like CBD and THC. CBG interacts with the body’s endocannabinoid system (ECS), a complex network of receptors found throughout the body, including the immune system and nervous system.
CBG’s potential anti-cancer effects are attributed to its interaction with the ECS. Studies have shown that CBG can inhibit the growth of cancer cells by activating specific receptors (CB1 and CB2) in the ECS. These receptors play a crucial role in regulating various physiological processes, including cell growth and apoptosis (programmed cell death). By influencing these processes, CBG may help slow down tumor progression.
CBG and Tumor Progression
Recent studies demonstrate that CBG is an effective tumor suppressant. In one recent study, the effects of CBG, along with CBD and THC, on glioblastoma cells were compared. CBG and THC similarly reduced cell viability, while combining CBD with CBG was more effective than with THC. Both CBG and CBD induced cell apoptosis, and CBG also inhibited glioblastoma invasion, similar to CBD and the chemotherapy drug temozolomide. Adding THC did not provide additional benefits, suggesting that CBG may be a better option for future clinical studies on glioblastoma therapy.
Another study found that CBG induced apoptosis and showed positive effects on reducing cell growth in colorectal cancer cells. Interestingly, CBG deactivates the CB2 receptors, which is important for this type of cancer. CB2 receptor activation has been linked to colon cancer progression, which suggests that cannabinoids that interact outside of the main cannabinoid receptors (like CBG) may prove most effective for this type of cancer.
A third research direction is currently looking at CBG in pre-trial studies as a potential treatment for gastrointestinal cancer. While these tests are still in the pre-trial stage, they have found that CBG induces significantly higher rates of cancer cell death compared to other cannabinoids.
Older research also highlights CBG’s potential as a treatment for oral cancer. This is another case where CBG doesn’t interact with the two best-known ECS receptors, CB1 or CB2. Instead, a different receptor type entirely– the TRPM8 receptors– play the primary role in this anti-cancer mechanism.
Combining CBG with Other Treatments
CBG holds immense potential as an adjuvant therapy alongside conventional cancer treatments like chemotherapy and radiation. Studies have indicated that CBG may enhance the efficacy of these treatments while reducing their side effects, such as pain. CBG’s anti-inflammatory properties may help reduce the inflammation caused by chemotherapy, leading to better treatment outcomes.
Additionally, lab tests and studies have shown that CBG can be an effective treatment for some side effects of chemotherapy. One study found that CBG robustly improved weight loss induced by Cisplatin, a chemotherapy medication used to treat a number of cancer types. This type of medication is powerful and can create problems with gut function and liver toxicity– which the study found were all partially normalized by CBG.
Additionally, CBG has shown synergistic effects when combined with other cannabinoids, such as THC and CBD. This phenomenon, known as the entourage effect, suggests that cannabinoids work together to enhance their therapeutic potential. Further research is needed to explore the optimal combinations and dosages for the best results.
Taking CBG for Cancer
The potential of CBG in reducing tumor progression is an exciting area of research that offers hope in the fight against cancer. With its unique properties and mechanisms of action, CBG shows promise as an anti-cancer agent by inhibiting abnormal cell growth and reducing inflammation.
The easiest way to take CBG for tumors or other cancer-related issues is to use a high-quality, lab-tested CBG oil. Our CBG oil is a full-spectrum oil, meaning you can benefit from the entourage effect, and is third-party lab tested for your peace of mind.
For those interested in using CBG for cancer, we always recommend when and wherever possible that licensed cannabis medical professionals be consulted. Contact us for a referral by email at firstname.lastname@example.org, or by phone at (800) 683-4807 ext 1.
At Myriam’s Hope Hemp, we believe that everybody should have access to the information they need to make choices about their health. Contact us today if you have any questions about our premium CBD and CBG, as well as our other cannabinoid products like CBGA!
- Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells.
- Cannabinoids CBC and CBG exhibit anti-tumour properties on cancer cells
- Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
- Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol
- Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid
- In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties